Aktuelle publikasjoner

På denne siden finner du referanser med direkte link til abstraktet eller fullteksten av publikasjonen. De utvalgte publikasjonene omhandler fortrinnvis behandling av prostatakreft og studier som blir referert under Redaktørens hjørne.

Ønsker du noen av artiklene i fulltekst tilsendt kan du sende en mail til Medisinsk informasjon, AstraZeneca AS: medinfo-norge@astrazeneca.com

Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group.
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
J Urol 2004;172:1865-70

Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group.
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6
J Urol 2004;172:1871-76

Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4.
Quality of life after radical prostatectomy or watchful waiting
N Engl J Med 2002;347(11):790-796

Iversen P, Tammela T, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson J, Persson B, Carroll K.
A randomised comparison of Bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian prostatic cancer group study no. 6
European Urology 2002;42:204-211

See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group.
Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program
Journal of Urology 2002;168:429-435

Ahmed S, Trump DL
The case of early androgen deprivation: the data should not be ignored.
Urologic Oncology 2002;7:77-80

Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M.
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase lll randomised trial
The Lancet 2002;360(13):103-108

Chodak GW, Kolvenbag GJ
Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer
Prostate Cancer and Prostatic Diseases 2001;4:72-80

See W.A , McLeod D, Iversen P, Wirth M
The bicalutamide Early Prostate Cancer Program. Demography.
Urol. Oncol.. 2001 Mar;6(2):43-47.

Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A.
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Urology. 2001 Aug;58(2):146-51.

Belldegrun A
What's hot in the prostate?
Pros Ca and Prostatic diseases 2001;4:67-70

Wirth MP, Froehner M.
Perspectives in adjuvant treatment of prostate cancer.
Urol Int 2002;68(1):1-5

Kolvenbag GC
The Prostate Cancer Continnuum: The Role of Bicalutamide(Casodex®)
The Prostate Journal 2001;3(1):2-13

Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L
No randomised trial of prostate cancer screening in Norway
The Lancet Oncology 2001;2:741-745

Lilleby W, Paus E, Skovlund E, Fossa SD.
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Prostate 2001 Feb 1;46(2):126-33

Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M.
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
N Engl J Med 1997 Jul 31;337(5):295-300

Andersson J, Ekman P, Egevad L, Hellstrom M.
Relatively high risk of treatment failure after prostatectomy: tumour grade, histopathological stage and the preoperative serum PSA level are key prognosticators.
Scand J Urol Nephrol. 2001 Dec;35(6):453-8.

Anderson J
Quality of life aspects of treatment options for localized and locally advanced prostate cancer.
Eur Urol 2001;40 Suppl 2:24-30